EPA:ALPRE - Euronext Paris - Matif - FR0010169920 - Common Stock - Currency: EUR
EPA:ALPRE (3/7/2025, 7:00:00 PM)
3.86
-0.08 (-2.03%)
The current stock price of ALPRE.PA is 3.86 EUR. In the past month the price increased by 1.58%. In the past year, price decreased by -8.96%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Predilife SA operates as a medical technology company. The company is headquartered in Villejuif, Ile-De-France and currently employs 19 full-time employees. The company went IPO on 2018-12-21. The firm operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.
PREDILIFE SA
Igr Campus Cancer 1 Batiment Maurice, 39 Rue Camille Desmoulins
Villejuif ILE-DE-FRANCE FR
Employees: 19
Company Website: https://www.predilife.com
Investor Relations: http://www.predilife.com/en/press-releases-and-publications/
Phone: 33142114211.0
The current stock price of ALPRE.PA is 3.86 EUR. The price decreased by -2.03% in the last trading session.
The exchange symbol of PREDILIFE SA is ALPRE and it is listed on the Euronext Paris - Matif exchange.
ALPRE.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALPRE.PA and the average price target is 21.34 EUR. This implies a price increase of 452.81% is expected in the next year compared to the current price of 3.86. Check the PREDILIFE SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PREDILIFE SA (ALPRE.PA) has a market capitalization of 14.51M EUR. This makes ALPRE.PA a Nano Cap stock.
PREDILIFE SA (ALPRE.PA) currently has 19 employees.
PREDILIFE SA (ALPRE.PA) has a support level at 3.56 and a resistance level at 3.9. Check the full technical report for a detailed analysis of ALPRE.PA support and resistance levels.
The Revenue of PREDILIFE SA (ALPRE.PA) is expected to grow by 115.63% in the next year. Check the estimates tab for more information on the ALPRE.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALPRE.PA does not pay a dividend.
PREDILIFE SA (ALPRE.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.25).
ChartMill assigns a technical rating of 2 / 10 to ALPRE.PA. When comparing the yearly performance of all stocks, ALPRE.PA is a bad performer in the overall market: 81.86% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ALPRE.PA. Both the profitability and financial health of ALPRE.PA have multiple concerns.
Over the last trailing twelve months ALPRE.PA reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -15.85% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -193.45% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 87% to ALPRE.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -16.5% and a revenue growth 115.63% for ALPRE.PA